摘要
目的评价复方甘草酸苷治疗慢性丙型肝炎的疗效和安全性。方法检索并选取国内公开发表的有关复方甘草酸苷治疗慢性丙型肝炎的随机对照试验(RCT)研究,对纳入文献的质量用Jadad计分表评价,对药物疗效用RevMan 4.2进行Meta分析。结果 5项RCT纳入Meta分析,与对照组比较,治疗组丙氨酸转氨酶(ALT)[P=0.04<0.05,WMD=-40.06,95%CI(-79.02,-1.09)]、天冬氨酸转氨酶(AST)[P=0.01,WMD=-0.31,95%CI(-0.55,-0.06)]、血清总胆红素(TBiL)[P=0.007<0.05,WMD=-2.39,95%CI(-4.12,-0.66)]差异有统计学意义。结论复方甘草酸苷治疗慢性丙型肝炎有较好疗效,且无明显不良反应,但由于现有的研究质量较差,尚需设计严谨的多中心、大样本RCT来进一步证实。
Objective To evaluate the curative effect of compound glycyrrhizin nucleoside treatment of chronic hepatitis c, and security. Methods To retrieve and select domestic published related compound glycyrrhizin glucoside in the treatment of chronic hepatitis c randomized controlled trial （RCT） study, using the Jadad score table about the quality of the included in the literature evaluation, Meta analysis was carried out on the drug efficacy using RevMan 4.2. Results The five RCT included in the Meta analysis, compared with control group, treatment group alanine aminotransferase （ALT） （P=0.04〈0.05, WMD=40.06, 95%CI （79.02, 1.09）, aspartate amiuotransferase （AST） （P--0.01, WMD=0.01, 95% CI （0.55, 0.06）, serum total bilirubiu （TBiL） （P=0.007〈0.05, WMD=2.39, 95% CI （4.12, 0.66） the difference was statistically significant. Conclusion Compound glycyrrhizin glucoside have good curative effect for the treatment of chronic hepatitis c, and no obvious adverse reaction, but due to the poor quality of the existing research, still need to design the rigorous multicenter, large sample RCT to confirm.
出处
《中国医药指南》
2013年第29期14-16,共3页
Guide of China Medicine
关键词
复方甘草酸苷
随机对照试验
慢性丙型肝炎
META分析
Compound glycyrrhizin glucoside
Randomized controlled trial
Chronic hepatitis C
Meta analysis
